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Abstract  
FGFR1 and FGFR2 are amplified in many tumour types, yet what determines response to 
FGFR inhibition in amplified cancers is unknown.  In a translational clinical trial we show that 
gastric cancers with high-level clonal FGFR2 amplification have a high response rate to the 
selective FGFR inhibitor AZD4547, whilst cancers with sub-clonal or low-level amplification 
did not respond. Using cell lines and patient derived xenografts models, we show high-level 
FGFR2 amplification initiates a distinct oncogene addiction phenotype, characterised by 
FGFR2 mediated transactivation of alternative receptor kinases, bringing PI3 kinase/mTOR 
signalling under FGFR control. Signalling in low-level FGFR1 amplified cancers is more 
restricted to MAPK signalling, limiting sensitivity to FGFR inhibition. Finally, we show 
circulating tumour DNA screening can identify high-level clonally amplified cancers. Our data 
provides a mechanistic understanding of the distinct pattern of oncogene addiction seen in 
highly-amplified cancers and demonstrate the importance of clonality in predicting response 
to targeted therapy. 
 
Statement of Significance  
Robust single agent response is only seen in high-level FGFR amplified cancers, with copy 
number level dictating response to FGFR inhibition both in vitro, in vivo, and in the clinic. 
High-level amplification of FGFR2 is relatively rare in gastric and breast cancers, and we 
show that screening for amplification in circulating tumour DNA may present a viable 
strategy to screen patients.  
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Introduction  
Activation of the fibroblast growth factor receptors (FGFRs) is a common oncogenic 
mechanism, with activation of the FGFRs occurring in a subset of nearly all common cancers 
(1, 2). Activating genetic events in carcinomas include receptor amplification, mutation, and 
generation of aberrant receptor fusions through translocation (1, 2). There is limited 
understanding of how these diverse oncogenic events differ in their signalling to downstream 
pathways, and consequently whether the same or different therapeutic approaches may be 
required to treat cancers with different genetic events. 
Amplification of FGFR1 is found in ~10% breast cancer and ~15% squamous lung cancers, 
with amplification of FGFR2 found in ~8% gastro-oesophageal cancer and ~2% breast 
cancer (1). We conducted a translational clinical trial to assess whether cancers with 
amplification of FGFR1 or FGFR2 respond to the selective FGFR inhibitor AZD4547 (3). 
Patients were screened for the presence of amplification using criteria defined for detection 
of HER2 amplification (4). Through the clinical trial we identify that high-level copy number 
amplification is required for response to selective FGFR inhibition. Through analysis of 
functional genomic screens (5), we show that high level FGFR2 amplified cell lines have a 
distinct oncogene addiction phenotype, that is characterized by PI3 kinase and mTOR 
signalling becoming dependent on FGFR signalling. We investigate the factors that 
predispose to oncogene addiction phenotype, and the implications for response to inhibitors 
targeting amplified receptor tyrosine kinases. 
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Results 
FGFR2 amplified cancers have a high response rate to AZD4547 
We assessed the activity of the FGFR selective inhibitor AZD4547 in FGFR1 amplified 
breast cancer and FGFR2 amplified gastro-oesophageal cancer. We screened 341 patients 
with advanced cancer by fluorescent in situ hybridization (FISH) for the presence of gene 
amplification, identifying FGFR1 amplification in 18% advanced estrogen receptor positive 
breast cancer and FGFR2 amplification in 9.0% advanced gastro-oesophageal cancer. Eight 
patients with FGFR1 amplified breast cancer and nine with FGFR2 amplified gastro-
oesophageal cancer were treated with AZD4547 in a translational clinical trial 
(Supplementary Fig. 1A). One FGFR1 amplified (12.5% response rate) and three FGFR2 
amplified (33% response rate) patients had confirmed responses to AZD4547 (Fig. 1A and 
B), reaching the predefined criteria for efficacy in the FGFR2 amplified cohort. The 
responses were durable with a median progression free survival of responding patients of 
6.6 months (range 6.2-10.5 months, Fig. 1A). Comparison of 18F-fludeoxyglucose positron 
emission tomography (FDG-PET) in responding patients between baseline and day 15 
demonstrated a substantial reduction in glucose uptake in all responding FGFR2 amplified 
gastric cancers, although there was no change in the FGFR1 amplified breast cancer (Fig. 
1C). The FDG-PET responses were maintained at 8 weeks (Supplementary Fig. 1B). Two 
additional patients with FGFR2 amplified gastric cancer had a response in day 15 FDG-PET 
but did not have a confirmed response by RECIST criteria (Patients 135 and 99, 
Supplementary Fig. 1C). Serum phosphate was elevated from baseline in the majority of 
patients on the study (Supplementary Fig. 1D, P=0.0002 Wilcoxon matched pairs-signed 
rank test), as a pharmacodynamic marker of interrupting FGF23 signalling by FGFR 
inhibition (6). There was no correlation of response to change in phosphate level. Both a 
continuous and intermittent schedule of AZD4547 were used in the trial (methods). Of the 
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responders, patient 21 and 207 were treated on the intermittent schedule, and patients 269 and 
patient 316 received continuous treatment. 
 
High-level clonal FGFR2 amplification is a therapeutic target for selective FGFR 
inhibitors 
We investigated the pathological basis of response in FGFR amplified cancers, the relatively 
high response rate of FGFR2 amplified gastric cancers compared to FGFR1 amplified breast 
cancer, with FDG-PET reductions only in FGFR2 amplified cancers. We assessed relative 
FGFR copy number by digital PCR in baseline tumour biopsies of patients treated in the 
clinical trial. For all patients with gastric cancer, the gastro-esophageal disease was biopsied 
by endoscopy. The response of the site biopsied was concordant with response with other 
sites of disease. Multiple different tumour sites were biopsied in patients with breast cancer. 
In the one patient who responded, the biopsied site responded along with other non-biopsied 
sites. 
 
Cancers with high copy number (high-level) FGFR amplification were more likely to respond 
to AZD4547 (P=0.0026 Mann-Whitney U Test, Fig. 2A), with response only observed in 
cancers with high-level amplification in this trial. Within FGFR2 amplified cancers, high-level 
amplification was associated with a substantially higher expression of both FGFR2 mRNA 
and FGFR2 protein assessed by immunohistochemistry on baseline biopsies (Fig. 2B and 
Supplementary Fig. 2A and 2B). Truncated isoforms of FGFR2 have been shown to be 
potentially important for FGFR2 oncogenic transformation (7, 8). Only cancers with high-
level FGFR2 amplification had expression of the truncated FGFR2-C3 isoform although at 
varying levels suggesting that the C3 isoform was not critical to established cancers 
(Supplementary Fig. 2C). However, expression of FGFR2-C3 may have potential as a 
biomarker for enrichment of patients likely to respond to FGFR inhibition. 
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We explored the role of clonality in response to AZD4547 in FGFR2 amplified cancers, using 
in situ heterogeneity mapping (online methods). Two responding patients had clonal 
homogeneously amplified tumours (>99% tumour cells FGFR2 amplified), the third patient 
having insufficient residual baseline tissue to make an assessment, whereas all non-
responding patients had tumours with sub-clonal heterogeneous amplification with the 
presence of non-amplified tumour cells (Fig. 2C). In particular, heterogeneity in FGFR2 
amplification was noted in patient 135 that had a high-level amplified tumour that did not 
respond to AZD4547.  There was limited evidence of heterogeneity and the presence of non-
amplified tumour cells in patient 99 that also did not respond. Both patient 135 and 99 had 
day 15 FDG-PET responses (Supplementary Fig 1C), suggesting that sub-clonality may 
explain the clinical pattern of FDG response that did not subsequently result in tumour 
shrinkage and clinical response. We compared paired gene expression between baseline 
and day 15 on-treatment biopsies with a custom Nanostring panel. In the heterogeneously 
amplified tumour from patient 135, high FGFR2 mRNA expression was lost at day 15 (Fig. 
2D), whilst in the homogeneously amplified cancers high FGFR2 mRNA expression was 
maintained at day 15. Similarly, in patient 135 FGFR2 copy number was substantially 
reduced at day 15 (Supplementary Fig. 2D). These findings may reflect the inherent difficulty 
of sampling in a heterogeneous tumour, but equally could reflect clonal selection by 
AZD4547. In paired gene expression analysis, the one FGFR1 amplified cancer that 
responded to AZD4547 had upregulation of estrogen receptor target genes in the day 15 
biopsy (Supplementary Table 1), suggesting that unregulated estrogen signalling may have 
limited sensitivity to the FGFR inhibitor in this tumour. 
High-level FGFR2 amplification occurred in only 5% gastric cancers (7/135, arbitrarily 
defined as FISH ratio>5), a prevalence that may present a barrier to future drug 
development. We assessed whether screening for amplification in circulating free plasma 
DNA could identify high-level clonal amplified cancers (9). FGFR2 copy number was 
elevated in plasma DNA of all three responding patients (Fig. 2E), and also in patient 99 who 
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had a response in day 15 FDG-PET (Supplementary Fig. 1C). However, FGFR2 copy 
number was not elevated in plasma DNA of patient 135 with the sub-clonal amplification, 
and not in low-level amplified cancers, suggesting that plasma assessment has potential to 
screen for high-level and clonal amplified cancers, to overcome the challenge posed by 
screening for amplifications on tumour biopsies. 
 
High-level FGFR2 amplified cancer models are highly sensitive to FGFR inhibition  
This data suggested that high-level clonal amplification, in particular for FGFR2 amplified 
cancers, may be required for response to selective FGFR inhibitors, and we investigated 
why high-level amplification may associate with distinct addiction to FGFR signalling. We 
examined FGFR copy number in a panel of 74 cancer cell lines (n=25) and gastric tumours 
(n=49). A distinct bimodal pattern of FGFR2 copy number was observed (Bimodality index 
2.74, Fig. 3A), suggesting a distinct high-level FGFR2 amplified group (10). In contrast, in a 
panel of 82 cancer cell lines (n=22) and breast tumours (n=60), there was a less pronounced 
bimodal distribution in FGFR1 amplification (Bimodality index 1.3, Fig. 3A). This suggested 
that high-level amplification was seen more distinctly in FGFR2 amplified cancers.  
In a panel of FGFR driven cell lines (Supplementary Table 2), FGFR auto-phosphorylation 
(Tyr653/654 loop phosphorylation) was very substantially increased in high-level FGFR2 
amplified cell lines (Fig. 3B), suggesting that high-level FGFR2 amplification resulted in 
FGFR hyper-activation, potentially reflecting the very high level of FGFR2 copy number seen 
in FGFR2 amplified cell lines (Supplementary Fig. 3A). Furthermore, FGFR2 high level 
amplified cell lines were more sensitive to FGFR inhibitors AZD4547 and PD173074 in vitro 
than low-level FGFR1 amplified cell lines, both in terms of lower EC50 and increased 
maximal effect (Fig. 3C and D). Similarly, FGFR2 amplified cell lines were more sensitive to 
PD173074 than FGFR2 mutant cell lines (P=0.0357 Mann-Whitney U Test, Supplementary 
Fig. 3B), and the level of CNV correlated with sensitivity to FGFR inhibition (R=0.8095, 
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P=0.0218, Supplementary Fig 3C). In addition, AZD4547 robustly increased caspase 3/7 
activation only in FGFR2 amplified cell lines (Fig. 3E).  
To validate these findings, we established patient derived xenografts (PDX) in nude mice 
from the baseline biopsies of two FGFR2 clonally amplified patients who responded to 
AZD4547 in the clinic (Fig. 1). To validate the models we performed whole exome 
sequencing was on the patient’s archival diagnostic tumour biopsies, baseline tumour 
biopsies, germline, and on the established PDX models. There was high agreement in 
somatic mutations between the PDX models and the patient’s baseline tumour suggesting 
an absence of substantial genetic drift and that the models were an accurate representation 
of the baseline tumour biopsy (FG42/pt316 R=0.86, FG51/pt269 R=0.85, Supplementary Fig 
3D). Both PDX models, FG51 (pt269) and FG42 (pt316), were highly sensitive to AZD4547 
in vivo, in FG51 median 70% tumour shrinkage and 2/5 complete responses, and in FG42 
median 74% tumour shrinkage and 0/5 complete responses (Fig. 3F). AZD4547 induced an 
apoptotic response as assessed by cleaved caspase 3 on PDX tumour lysates (Fig. 3G).  
 
High-level FGFR2 amplification initiates a distinct oncogene addiction phenotype 
characterised by FGFR dependent control of PI3K-AKT signalling  
To investigate why high-level FGFR2 amplified models demonstrated high sensitivity to 
FGFR inhibitors, we analysed a functional genomic screen of a panel of FGFR driven cell 
lines transfected with an siRNA screening library directed against the kinome and 
phosphatome (5). Using supervised hierarchical clustering we identified the siRNAs that 
selectively modified sensitivity to the FGFR inhibitor PD173074 (5) in FGFR2 amplified cell 
lines, compared to other FGFR driven cell lines, identifying a distinct set of siRNAs that was 
strongly enriched for components of the PI3K pathway and canonical NFκB signalling (Fig. 
4A and Supplementary Fig. 4A). Increased sensitivity to FGFR inhibition was confirmed with 
multiple different siRNA for NFκB signalling pathway components IKBKB and MAP3K7 
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(Supplementary Fig. 4B). PTEN siRNA reduced the sensitivity of FGFR2 amplified cell lines 
to PD173074 with little effect in other FGFR driven cell lines (Fig. 4A and Supplementary 
Fig. 4A, P=0.009 Mann Whitney U Test). In validation work, PTEN silencing reduced the 
sensitivity of FGFR2 amplified breast cancer cell line SUM52 to PD173074 in clonogenic 
assays (Fig. 4B), induced AKT phosphorylation, and increased the concentration of 
PD173074 required to inhibit AKT phosphorylation (Fig. 4C). 
These data suggested that FGFR2 amplified cell lines may show a distinct reliance on PI3 
kinase signalling compared to other FGFR driven cell lines. Interestingly in gastric cancer 
TCGA data, PIK3CA mutation occurred in 23% (48/206) non-amplified cancers, and in 0% 
(0/13, p=0.036 Fishers exact test) FGFR2 amplified cancers, suggesting distinct 
mechanisms of PI3 kinase pathway activation (11). We studied downstream signalling in 
response to PD173074 across a panel of FGFR driven cell lines (Fig. 4D and Supplementary 
Fig. 4C). Phosphorylation of ERK1/2 was reduced in all cell lines by PD173074 (Fig. 4D and 
Supplementary Fig. 4C) in keeping with the physiological effects of FGFR signalling through 
the MEK-ERK pathway (1). In contrast, only in FGFR2 amplified cell lines was AKT Ser473 
phosphorylation reduced by PD173074, with no reduction in FGFR1 amplified cell lines as 
well as minimal reduction in FGFR2 and FGFR3 mutant cell lines (Fig. 4D and 
Supplementary Fig. 4C). In FGFR1 amplified cell lines, PD173074 also had little effect on 
AKT Thr308 or PDK1 Ser241 phosphorylation (Supplementary Fig. 4D). We established in 
vitro primary spheroid cultures from FGFR2 amplified PDXs FG51 (pt269) and FG42 (pt316). 
In these primary spheroid cultures, AZD4547 inhibited AKT phosphorylation (Fig. 4E) 
suggesting a similar pattern of FGFR dependent PI3K signalling was seen in patient derived 
material. 
AZD4547 inhibited 4EBP1 phosphorylation in FGFR2 amplified cell lines (Fig. 4F) and PDX 
derived spheroids (Fig. 4E), suggesting that mTOR signalling was substantially inhibited by 
FGFR inhibition. In contrast, AZD4547 had minimal effect on 4EBP1 phosphorylation in 
FGFR1 amplified cell lines (Fig. 4F). AZD4547 decreased levels of phospho-S6 in both 
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FGFR1 (2/3) and FGFR2 (2/3) amplified cell lines, in keeping with the potential regulation of 
S6 phosphorylation by MEK-ERK MAPK signalling (Supplementary Fig. 4E). In FGFR1 
amplified cell lines inhibition of mTOR was synergistic with FGFR inhibition (Supplementary 
Fig.4F), converting a cytostatic effect of FGFR inhibition alone to a cytotoxic effect 
(Supplementary Fig. 4G), illustrating the importance of mTOR inhibition in initiating a 
cytotoxic response. Finally, in FGFR2 amplified cell lines AZD4547 inhibited eIF4G loading 
onto 7methyl GTP (Fig. 4G) and inhibited nascent protein synthesis determined using 
incorporation of the methionine analog L-azidohomoalanine (Fig. 4H), demonstrating 
inhibition of mTOR signalling and cap dependent translation. 
 
Amplified FGFR2 activates PI3 kinase in part through transactivation of multiple 
alternative receptor tyrosine kinases. 
We set out to determine how PI3 kinase signalling becomes FGFR dependent in highly 
amplified cell lines. FGFRs signal to PI3 kinase in a canonical fashion through binding of the 
FGFR specific adapter protein FRS2 to GRB2 and GAB1 (12). Silencing GRB2 modestly 
increased AKT phosphorylation in the SUM52 FGFR2 amplified cell line, and silencing 
FRS2α resulted in only a minor reduction of AKT phosphorylation (Supplementary Fig. 5A-
B). In addition the PI3 kinase regulatory subunit p85 (PIK3R1) did not appear to associate 
with FGFR2 as assayed by immunoprecipitation (Fig. 5A), suggesting that FGFR2 signalling 
controlled PI3 kinase signalling through a non-canonical mechanism. 
To explore how FGFR2 activated PI3 kinase, we assessed the phosphorylation of 49 
receptor tyrosine kinases (RTK) in response to FGFR inhibition, noting reduced tyrosine 
phosphorylation of all receptor tyrosine kinases assayed in SUM52 (Fig. 5B), and FGFR3, 
ERBB3 and partially EGFR in the FGFR2 amplified gastric cancer SNU16 cell line (Fig. 5B). 
Similarly in PDX model FG42 (pt316) there was a similar pattern of phosphorylation of 
FGFR2, EGFR and ERBB3, with substantial reduction in phosphorylation of all RTKs to 
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FGFR inhibition in RTK arrays and by western blot (Figure 5C). In contrast, PD173074 
treatment had little effect on RTK phosphorylation in the FGFR1 amplified cell line JMSU1 
(Supplementary Fig. 5C). Phosphorylation of ERBB3 Tyr1289 and EGFR Tyr1068 was 
inhibited by PD173074 in FGFR2 amplified cell lines (Supplementary Fig. 5D), with ERBB3 
phosphorylation unaffected by inhibition of EGFR/HER2 with gefitinib or lapatinib 
(Supplementary Fig. 5E).  
The interaction between ERBB3 and p85 PI3K assayed by immunoprecipitation was 
inhibited by PD173074 (Fig. 5D), and silencing of ERBB3 with multiple different siRNA 
partially reduced AKT phosphorylation in SUM52 and in SNU16 (Fig. 5E). ERBB3 was not 
observed to interact with FGFR2, suggesting that FGFR2 may not phosphorylate ERBB3 
directly (Fig. 5D). Among a panel of cell lines, SNU16 were observed to have high 
expression of IGF1R (Supplementary Fig. 5F). In contrast to ERBB3, IGF1R phosphorylation 
was not decreased by PD173074 in SNU16 (Fig. 5B and 5F), whilst inhibition of IGF1R with 
AEW541 also blocked AKT phosphorylation (Fig. 5G) at concentrations that had no effect on 
FGFR2 auto-phosphorylation (Supplementary Fig. 5G). Similarly, levels of AKT 
phosphorylation were decreased by knockdown of IGF1R using siRNA (Supplementary Fig 
5H). Therefore, both FGFR2 and IGF1R signalling were necessary for signalling to PI3K-
AKT in SNU16. Activation of PI3 kinase catalytic activity requires binding of GTP bound RAS 
to p110α, or GTP bound CDC42/RAC1 to p110β (13), and release from inhibitory effects of 
the p85 regulatory subunit (14). Inhibition of FGFR signalling with PD173074, not IGF1R 
signalling with AEW541, reduced RAS activation in SNU16 (Fig. 5H). Conversely, p85 PI3K 
that did not associate with FGFR2 (Fig. 5A), bound to IRS1 in an IGF1R kinase dependent 
fashion (Fig. 5I). Therefore PI3 kinase pathway signalling is activated through the combined 
effects of FGFR2 dependent activation of RAS, and p85 binding to ERBB3 and IGF1R/IRS1. 
FGFR2 signalling trans-phosphorylates ERBB3 to act as a scaffold to bind p85, with IGF1R 
signalling promoting IRS1 binding to p85, to thereby activate PI3 kinase signalling. 
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Discussion 
The diversity of mechanisms through which FGFR signalling are activated in cancer present 
a clinical translational challenge, how similar or dissimilar are the different mechanisms of 
activating FGFR signalling? With a translational clinical trial we identify that cancers with 
high-level FGFR2 amplification form a distinct group characterized by a strong oncogene 
addiction phenotype and high sensitivity to AZD4547. High-level amplification initiates 
distinct signalling characterized by transactivation of alternative receptor tyrosine kinases to 
bring PI3 kinase and mTOR signalling under control of FGFR2.  
Our study has implications for targeting amplified receptor tyrosine kinases (RTKs). The 
archetypal model for targeting amplified RTKs is that of HER2 amplification in breast cancer 
(15), where the level of HER2 amplification does not affect sensitivity to the HER2 targeting 
antibody trastuzumab (16). Our data suggests that HER2 amplification in breast cancer may 
be a limited model for targeting other amplified RTKs, and that criteria developed to identify 
cancers sensitive to HER2 targeting (a HER2 to centromere copy number ratio of >=2, 
and/or absolute HER2 copy number >=6) may not necessarily translate to other RTKs. 
HER2 has unique biology amongst RTKs, lacking an activating ligand and with inherent 
potential for constitutive activation when over-expressed, and a very tight relationship 
between the presence of amplification of any copy number level and overexpression of 
HER2 (17). In contrast, high-level FGFR copy number amplification associates with 
sensitivity to FGFR inhibition, with high-level amplification resulting in high expression of 
FGFR2 initiates a distinct oncogene addiction phenotype. In addition, low-level FGFR1/2 
amplification does not strongly associate with FGFR over-expression (4). Our data strongly 
suggests that clinical trials targeting FGFR, and potentially other RTKs, should consider 
higher thresholds for amplification. We also demonstrate the importance of assessing 
amplification clonality in predicting durable responses to therapy, the potential to assess the 
degree of heterogeneity using automated in situ heterogeneity mapping of FISH, and that it 
may be possible to identify patients with highly FGFR2 amplified gastric cancers by analysis 
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of FGFR2 copy number in cell free plasma DNA, providing a potential simple strategy to 
screen patients for rare amplifications. 
We show that high-level FGFR2 amplification initiates an oncogene addiction phenotype in 
part through activation of alternative receptor kinases that brings PI3 kinase pathway 
signalling under the control of FGFR signalling. FGFR2 lacks consensus binding sites for the 
PI3 kinase p85 regulatory subunit, and we show that over-expressed FGFR2 activates PI3 
kinase signalling indirectly through cooperation with other RTKs including ERBB3 (18) and 
IGF1R. FGFR2 trans-phosphorylates ERBB3, via a mechanism not identified in these 
studies, to promote binding to p85 PI3K, with ERBB3 acting as a scaffold protein. In 
contrast, FGFR2 cooperates with IGF1R in a related but distinct fashion, where FGFR2 
promotes PI3 kinase signalling through RAS activation while IGF1R signalling promotes p85 
binding via IRS1 (Supplementary Fig. 6). For lower-level FGFR1 amplified cell lines PI3 
kinase and mTOR signalling is not blocked by FGFR inhibition and this limits the sensitivity 
of these cell lines to FGFR inhibition, characterised by a lack of FGD-PET changes seen in 
the FGFR1 amplified responding patient in our clinical-translational trial. Both PI3 kinase and 
mTOR inhibitors synergise with FGFR inhibition in these cell lines (Supplementary Fig.4), 
identifying a potential combination strategy for FGFR1 amplified cancers that do not exhibit a 
strong oncogene addiction phenotype that can be investigated in future research. 
In this study we identify the importance of high-level clonal amplification in predicting 
response to FGFR selective inhibitors. High-level amplifications are of relatively low 
prevalence and we show that high-level clonal FGFR2 amplification can be detected through 
ctDNA screening, opening up a screening strategy to facilitate future development of drugs 
targeting amplified receptor tyrosine kinases.  
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Methods 
Clinical Trial Design 
The FGFR trial (EudraCT No.:2011-003718-18) is a phase II, open label, non-randomised 
study of AZD4547 in patients with previously treated advanced FGFR amplified cancer. 
Written informed consent was obtained from all patients. The study was carried out in 
accordance with the Declaration of Helsinki and approved by local institutional review 
boards. The study originally consisted of three independent tumour cohorts (FGFR1 
amplified breast and squamous NSCLC and FGFR2 amplified gastroesophageal cancer), 
however due to poor accrual the lung cohort was closed to further recruitment. FGFR 
amplification testing was performed centrally on archival tissue and an FGFR ratio of ≥2.0 
(FGFR1:CEP8 and FGFR2:CEP10) was required for study entry. Prior to treatment patients 
underwent a biopsy and PET-CT, repeated on study between day 10-14. Treatment 
consisted of AZD4547 80mg twice daily (initially on an intermittent schedule of two weeks 
on, one week off which was subsequently amended to continuous dosing). Primary endpoint 
was confirmed overall response rate. The study followed a Simon 2 stage, optimal design. 
One or more responses were required in the initial 9 patients in each cohort, to recruit a total 
of 17 patients. Three of more patients were required to conclude that cohort had sufficient 
efficacy for further study. 
 
Cell lines and materials 
Bladder cells lines (RT112M, MGHU3, JMSU1, 97.7, 94.10) were from the laboratory of MA 
Knowles (19) in 2010. Ocum2M were obtained from the laboratory of Masakazu Yashiro 
(Department of Surgical Oncology, Osaka City University Graduate School of Medicine) in 
2010. All other cell lines were from the laboratory of A Ashworth in 2014 (Gene Function, 
Institute of Cancer Research, London). CAL120, MFE-296, MFE280, Kato III and An3CA 
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were originally obtained from CTS cell line service. BT-20, BT-483, BT549, CAMA1, 
DMS114, Hs578T, HCC1143, MDAMB134, MDAMB157, MDAMB175, MDAMB231, 
MDAMB361, MDAMB453, MCF12A, NCI-H1581, NCI-H520, T47D and ZR-75-1 were 
originally obtained from ATCC. MFM223, SUM44, SUM52, SUM149, and Snu16 were 
originally from Asterand. All cell lines were banked in multiple aliquots on receipt to reduce 
risk of phenotypic drift, and identity confirmed by STR profiling with the PowerPlex 1.2 
System (Promega). Cultured cell lines were subjected to STR profiling after approximately 
20 passages. In addition, cultured cell lines were tested once per month for the presence of 
mycoplasma. Cell lines were maintained in phenol red free DMEM, DMEM/F12, or RPMI 
with 10% FBS (PAA gold) and 2mM L-glutamine (Sigma-Aldrich, Dorset, UK).  
Antibodies used were phosphorylated AKT-Ser473 (4058), p-AKT T308 (2965), AKT (4691), 
phospho-4EBP1 T37/46 (2855), 4EBP1 (9452), phospho-ERK1/2-Thr202/Tyr204 (4370), 
ERK1,2 (9102), EGFR (2232), phospho-EGFR-Y1068 (3777), phospho-ERBB3-Y1289 
(4791), phospho-ERBB2-Y1221/1222 (2249), phospho-FGFR Y653/654 (3471), phospho-
FRS2a (3864), phospho-IGF1R (3918), IGF1R (9750), p85 PI3K (4292), PIK3CA (4255), 
PTEN (9559), phospho-ribosomal protein S6 (5364), ribosomal protein S6 (2217) (all Cell 
Signalling Technology, Danvers, MA). βactin (A5441) (Sigma). FGFR2 (sc-122), EGFR (sc-
03), PARP1 (sc-8003), and FRS2 (sc-8318) (Santa-Cruz Biotechnology, Santa Cruz, CA). 
ERBB3 (ab32121), and FGFR1 (ab76464) (Abcam). Grb2 (610111, BD Transduction 
Laboratories). p85 PI3K (ABS233, Millipore). AZD4547 and AZD8055 were provided by 
Astra Zeneca. CI-1040, GDC0941, KU0063794 and rapamycin were purchased from 
Selleckchem. PD173074 was from Sigma, gefitinib from Tocris. NVP-AEW541 from Cayman 
Chemicals. siRNA were from Dharmacon, Non-Targeting siRNA Pool#2, PTEN (MU-
003023-02) set of 4, PLK1 (siPLK1, M-003290-01), FR2Sa (MU-006440-02) set of 4, Grb2 
(MU-019220-00) set of 4, ErbB3 (MU-003127-03) set of 4 and IGF1R (MU-003012-05) set of 
4. siRNA against IKBKB and MAP7K3 were obtained from Dharmacon as part of a custom 
validation panel.  
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Tumour samples 
Additional tumour samples for analysis were obtained from existing trials. Gastric cancers 
(n=40) were from the MAGIC Trial (20). Breast cancers (n=42) were from tissue collection 
studies approved by multi-centre research ethics committees (ref.nos. 10/H0805/50 and 
11/LO1595). Written informed consent was obtained from all patients. The study was carried 
out in accordance with the Declaration of Helsinki and approved by local institutional review 
boards. 
 
Purification of DNA and RNA 
DNA and RNA was extracted from fresh frozen tumour samples using AllPrep™ micro 
DNA/RNA extraction kit (QIAgen 80284) and from FFPE tumour samples using AllPrep™ 
DNA/RNA FFPE extraction kit (QIAgen 80234). In both cases a section was stained with 
haematoxylin and eosin and tumour marked out by a pathologist. Sections were cut and 
stained with nuclear fast red and tumour macrodissected prior to nucleic acid extraction 
using the appropriate kit. Plasma DNA was extracted from 2ml of plasma using QIAamp® 
Circulating Nucleic Acid kit (QIAGEN 55114) according to the manufacturer’s guidelines. 
Purified RNA was quantified using the Qubit® RNA HS Assay kit (Life Technologies, 
Q32855). Purified DNA was quantified using the Qubit® dsDNA HS Assay kit (Life 
Technologies, Q32854). Plasma DNA was quantified by ddPCR using the RPPH1 CNV 
reference assay to calculate copies/well and multiplying by the c-value (3.3pg), an estimate 
of the mass of a single haploid human genome.  
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Droplet digital PCR 
Digital PCR was performed on a QX100 droplet PCR system (Bio-Rad). PCR reactions were 
prepared as previously described (9, 21). Briefly, emulsified PCR reactions were run on a 96 
well plate on a G-Storm GS4 thermal cycler incubating the plates at 95°C for 10 min followed 
by 40 cycles of 95°C for 15 sec, 60°C for 60 sec, followed by 10 min incubation at 98 °C. 
Plates were read on a Bio-Rad QX100 droplet reader using QuantaSoft v1.6.6.0320 
software. Copy number variation and gene expression for target genes were calculated as a 
ratio with multiplexed reference genes (Supplementary Table 3). Copy number variation 
assays were performed using 1-3ng genomic DNA, aiming to obtain a 300-600 reference 
droplets.  
For gene expression assays, cDNA was prepared using SuperScript® III First Strand kit (Life 
Technologies, 18080-051), according to the manufacturer’s guidelines using 50-200ng total 
RNA primed with random hexamers. ddPCR gene expression reactions (Supplementary 
Table 3) were typically set up with 1-5ng RNA equivalent of cDNA. Target expression was 
normalized using βActin and GAPDH references assays.  
 
In situ heterogeneity mapping  
Briefly, fluorescent sections were scanned into the MIRAX (Pannoramic) scanner at high 
magnification in the x, y and z planes and analysed using custom HALO software. Tumour 
compartments were marked by a pathologist and the entire tumour area analysed for 
amplified and non-amplified tumour cells. Amplified cells were determined as those with a 
ratio FGFR2:CEP10 >2, and assessed only in cells with CEP10 signals ≥2. Percentage 
amplified tumour cells and total copy number was calculated. A manuscript describing In situ 
heterogeneity mapping is under preparation. 
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Nanostring 
Probe sequences were custom designed and manufactured by Nanostring. Multiple probes 
were included against key genes including FGFR2. Probe specificity was confirmed using 
BLAT and Arrayviewer (Browser and Land software). The codeset was validated with cells 
lines and clinical tissue known to overexpress FGFR2.  In addition to genes of interest the 
Codeset included a number of housekeeping genes to correct for RNA input amount and/or 
quality. A positive control (Universal Human Reference RNA (UHR), Stratagene, catalog 
#75000-41) was run routinely to ensure consistency between runs. Input total RNA amount 
was 100ng or 5ul neat RNA for more dilute/poor quality samples (based on internal QC 
control criteria).  
Protocol was followed according to standard nCounter instructions. GEN2 Prep Station 
incubation time was set at the higher sensitivity setting (3hrs) and 280 Fields of View (FOV) 
were routinely captured unless otherwise noted. 
Data was normalized through an internally developed Pipeline Pilot Tool (publicly available 
for use on the Comprehensive R Archive Network, CRAN). In brief, data were log2 
transformed after being normalized in two steps: raw Nanostring counts were first 
background adjusted with a Truncated Poisson correction using negative control spikes 
followed by a technical normalization using positive control spikes. Data was then corrected 
for input amount variation through a Sigmoid shrunken slope normalization step using the 
mean expression of housekeeping genes. A transcript was designated as not detected if the 
raw count was below the average of the internal negative control raw counts plus 2 standard 
deviations. 
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siRNA screen 
Screening in 384 well plates with a Dharmacon siGENOME SMART pools library targeting 
all known protein kinases and phosphatases as described previously (5). To assess the 
effect of siRNA on growth/survival, the effect of siRNA in the vehicle plates was expressed 
as a Z score, with the standard deviation estimated from the median absolute deviation 
(MAD). To assess the effect of siRNA on sensitivity to PD173074 the log2 ratio between 
growth in PD173074 plates and vehicle plates was assessed and expressed as a Z score.  
 
Western Blotting 
Cell lines were grown on 35mm plates, treated as indicated, and lysed in NP40 lysis buffer, 
(1% v/v NP40, 10mM Tris.Cl pH8, 150mM NaCl, 1mM EDTA, 1mM DTT) supplemented with 
phosphatase (5mM Na4P2O7, 50mM NaF and 1mM NaVO4) and protease inhibitor cocktail 
(Roche, 11697498001). Cells were reverse transfected with siRNA 72 hours prior to lysis. 
Western blots were carried out with precast TA or Bis-Tris gels (Life Technologies). 
 
In vitro cell line assessment 
Clonogenic assays were conducted in 6 well plates, with 1000 cells seeded per well, and 24 
hours later cells exposed to vehicle, or the indicated treatments followed by growth in media 
for 2 weeks to allow colony growth. Colonies were fixed, stained with sulforhodamine B and 
counted. For PTEN siRNA clonogenics cells were treated for 1 week with PD173074 before 
wash out. For short-term survival assays, cells were exposed to indicated drugs with survival 
assessed after 72 hours exposure with Cell Titre-Glo cell viability assay (Promega, Madison, 
WI). To assess the effect of siRNA on drug sensitivity cells were reverse transfected at final 
siRNA concentration 20nM, at 48 hours post transfection plates were exposed to compound 
with survival was assessed after 72 hours exposure. To assess synergy cell lines were 
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plated in 384 well plates, and the following day exposed to fixed-ratio combinations of 
indicated drugs for 72 hours, with combination index assessed according to Chou and 
Talalay (22) using Calcusyn v2.1 (BIOSOFT, UK).  
 
Whole Exome Sequencing 
Genomic DNA (30-200ng) was fragmented to 200bp using a Covaris E Series and the 
resultant libraries were subjected to DNA Capture using SureSelect XT Human All Exon v4 
kit (Agilent) following manufacturer’s instructions. Final libraries were quantified using qPCR 
and clustered at a molarity of 14.5pM, sequencing was performed on an Illuimna HiSeq 2000 
using 2x75 cycles of version 3 SBS chemistry. Reads were aligned to the human reference 
genome (GRCh37) using BWA (v0.7.5a) (23). PCR duplicates were filtered out from the 
subsequent analysis using Picard-tools (v1.94) and variants were called using the GATK 
pipeline (v2.3.9) best practices (24). Somatic changes between germline, cancer samples 
and the PDX samples were investigated using MuTect (v1.1.4) (25) and filtered for on-target 
regions using bedTools (v2.17.0) Comparisons between allele frequencies of somatic 
mutations in the cancer and PDX samples were investigated using R (3.1.2). All sequencing 
data has been deposited in the NCBI Sequence Read Archive under accession SRP072158. 
 
Apoptosis assessment 
To assess apoptosis activated Caspase 3/7 activity was assessed using the Caspase-Glo® 
3/7 Assay according to manufacturer’s instructions (Promega, G8090) and adjusted for cell 
number as assessed by Cell Titre-Glo. 
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Phosphorylated RTK arrays 
 Cells and PDX were treated as indicated, lysates prepared using Lysis Buffer 17 and 
analysed using Human Phospho-RTK arrays (R&D Systems, ARY001B) according to the 
manufacturer’s guidelines. 
 
Immunoprecipitation 
Cells were treated as indicated and lysates prepared using NP40 lysis buffer (without DTT). 
The antibodies used for immunoprecipitation (IP) were p85 PI3K (ABS233, Millipore), ErbB3 
(Thermo Scientific, MS-262-P1) and FGFR2 (Santa Cruz, SC122). Control IPs were 
performed with normal mouse (SC2025) and rabbit IgG (SC2027, both Santa Cruz 
Biotechnologies). Veriblot anti-rabbit IgG (ab131366) and anti-mouse IgG (ab131368, both 
Abcam) HRP conjugated secondary antibodies were used for IPs. 500-1000mg of total 
cellular protein were incubated with the antibodies and the protein complexes precipitated 
using Protein G coated Dynabeads (Life Technologies, 10001D).  
 
Ras activation Assay 
Ras activation was determined using the Ras activation assay kit (Millipore, 17-218) 
according to the manufacturer’s guidelines. Briefly, cell lysates were prepared using Mg2+ 
Lysis/wash buffer (MLB). Samples were incubated with 10μg Ras assay reagent (Raf1 Ras 
binding domain-agarose) and incubated for 45min at 4˚C. Agarose beads were pelleted by 
centrifugation and washed 3 times with MLB. Agarose beads were resuspended in NuPAGE 
LDS sample buffer (Life Technologies). Samples were subjected to western blotting as 
previously described and blots probed using anti-Ras antibody (clone RAS10, 05-516, 
Millipore).  
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Methyl 7- GTP pull down 
Cells were lysed in NP40 lysis buffer. Pulldown mixes were prepared with 200μL containing 
200μg total cellular protein and 40μL 7methyl GTP-sepharose 4B beads (GE Healthcare, 
275025) to give a total volume of 240μL. Before use beads were washed twice with NP40 
lysis buffer. Pulldown mixes were incubated overnight at 4˚C. Beads were washed twice with 
NP40 lysis buffer, bound complexes eluted in western sample loading buffer and resolved on 
precast Bis-Tris gels (Life Technologies). 
 
AHA translation assay 
Protein synthesis was assessed using the Click IT AHA-Alexa Fluor 488 Protein Synthesis 
HCS Assay (Invitrogen C10289). L-azidohomoalanine (AHA) is an analog of methionine that 
contains an azide moiety. AHA that has been incorporated into proteins can be detected by 
ligation of a fluorescently labelled alkyne. 
Cells were grown on coverslips for 2 days, the media changed and treated with 50nM 
AZD4547 for 24h. Experimental conditions were removed and the cells washed with 
methionine free RMPI media (Sigma, R7513). Cells were treated with AHA prepared 
according to the manufacturer’s guidelines in methionine free RMPI media for 30mins. The 
AHA-media was removed, the cells washed twice with sterile cold PBS and the fixed with 4% 
paraformaldehyde (PFA). Coverslips were washed twice with 3%w/v BSA in PBS and then 
permeabilised in 0.5% v/v Triton-X100. Coverslips were washed before incubation with the 
Alexa Fluor 488 alkyne reaction mix for 30mins. Coverslips were washed and cells 
counterstained with Hoechst 33342. The coverslips were mounted onto glass slides with 
Vectastain (Vector, H1000). Fluorescently stained cells were imaged using an SP2 system 
Leica confocal microscope and images analysed using Adobe Photoshop Extended CS5.  
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Patient derived and cell line xenografts 
All animal experiments were performed under a UK Home Office Project License assessed 
by ethical review committee. 
Patient derived xenografts were established from fresh core biopsies collected into DMEM 
containing penicillin and streptomycin. Tissues samples were washed with 3 changes of 
DMEM containing antibiotics and implanted subcutaneously either on the flank or intra 
scapular of male Balb/c nude mice. Once tumours had established, they were collected, 
dissected and implanted into more male Balb/c nude mice for therapeutic experiments using 
AZD4547. Tumours were size matched and randomized to Control (Vehicle, 0.5% w/v 
hydroxypropylmethylcellulose, 0.1% v/v polysorbate 80 in water) or AZD4547 (5mg/Kg qd, in 
vehicle). Mice were dosed daily via oral gavage. 
NCI-H1581 xenografts were generated by subcutaneous injection of 5x106 cells in 50%v/v 
Growth Factor Reduced Matrigel (BD Biosciences, 356231) in 40 Balb/c nude mice. After 7 
days tumours were measured, size matched and the mice randomized to 4 experimental 
groups including Control (Vehicle), AZD4547 (5mg/Kg qd, in vehicle), AZD8055 (20mg/Kg 
qd, in vehicle) and AZD4547+AZD8055 (5mg/Kg qd and 20mg/kg qd respectively, in 
vehicle). Mice were dosed daily via oral gavage. Tumour size was assessed 3 times a week 
and expressed relative to the size at the start of treatment. To assess the signalling effect of 
the combinations mice with NCI-H1581 xenografts were dosed daily for 3 days. Mice were 
sacrificed 6 hours after the last treatment and tumours fixed with 4% paraformaldehyde in 
phosphate buffered saline.  
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Immunohistochemistry 
Following deparafinisation and rehydration, antigen retrieval was, followed by blocking of 
endogenous peroxidise activity using H2O2 block (Dako Envision Flex kit, K8000).  
For FGFR2 IHC, antigen retrieval was with pressure cooking in pH 9 retrieval buffer 
(DakoS2367). Sections were rinsed TBS-Tween 0.05% (TBS-T) and endogenous 
peroxidise blocked using H2O2 block (Dako Envision Flex kit, K8000). Sections were 
incubated for 1 hour with 1/10000 FGFR2 antibody (AZ AGG 2935-1C11, mouse 
monoclonal, from Astra Zeneca), followed by Envision+/HRP (Dako K4001) for 30 
minutes and staining with DAB. Sections were washed and counterstained in Gills 
Haematoxylin 
.
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Figure Legends 
Figure 1. Clinical activity of FGFR inhibitor AZD4547 in FGFR amplified breast and 
gastric cancer. 
A. Waterfall plot from 12 patients with FGFR1 amplified breast cancer or FGFR2 amplified 
gastric cancer, with maximum change in tumour size (Y axis) and duration on study (yellow, 
Z axis). Red are patients with confirmed partial response. Five patients who progressed 
clinically are not shown. 
B. Representative CT scans from baseline and 6 months in a patient with FGFR2 amplified 
gastric cancer with a partial response in liver metastases (marked with white arrow on 
baseline scan). 
C. 18F-FDG-PET scans from baseline (top) and day 15 (bottom) in patients who responded 
to AZD4547. Left 3 patients with FGFR2 amplified gastric cancer, and right 1 patient with 
FGFR1 amplified breast cancer. Red boxes mark abnormal areas of 18F-FDG uptake in 
baseline scan, and corresponding areas in the day 15 scan. Normal 18F-FDG uptake is 
seen in brain, heart, kidneys and bladder.  
 
Figure 2. High-level clonal amplification of FGFR2 that predicts for sensitivity to FGFR 
inhibitor can be identified through ctDNA screening 
A. FGFR1 copy number and FGFR2 copy number in breast and gastric cancers respectively 
assessed by digital PCR, from 17 patients treated with AZD4547. Red indicates patients who 
had a confirmed partial response to AZD4547, grey indicates patients with a partial 
metabolic change on day15 18F-FDG-PET but without a clinical response, and black 
patients without response. Response to AZD4547 is only seen in cancers with high-level 
copy number amplification (p=0.0026, Mann Whitney U Test), and partial metabolic change 
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in FGFR2 amplified cancers is only seen in cancers with high-level copy number 
amplification (p=0.0022, Mann Whitney U Test). 
B. FGFR2 mRNA expression assessed in baseline tumour biopsies by reverse transcription 
digital PCR (left), with FGFR2 immunohistochemistry (right), Colour coding as in part A. 
FGFR2 mRNA expression was normalized to reference genes βActin and GAPDH. Data is 
presented as the mean of the FGFR2:βActin and FGFR2:GAPDH ratios. 
C. Assessment of clonality of FGFR2 amplification by FGFR2 FISH on tumour sections, 
assessed with automated MIRAX analysis, divided by cancers that demonstrated clinical 
response (269 and 316) and no clinical response. Percentage of tumour cells with 
amplification is displayed, along with representative image from MIRAX analysis colour 
coded by the presence of amplified tumour cells (red) and non-amplified tumour cells (blue). 
The presence of non-amplified tumour cells in patient 99 was confirmed visually.  
D. Comparison of FGFR2 mRNA expression assessed by Nanostring™ in tumour biopsies 
from baseline and day 15. A substantial fall in FGFR2 expression is seen in the highly 
FGFR2 amplified but heterogeneous tumour from patient 135 potentially reflecting sub-clonal 
loss of FGFR2 over-expression tumour clone. 
E. Analysis of FGFR2 copy number in plasma DNA, from plasma samples taken at baseline. 
#, baseline plasma was not collected for patient 99, cfDNA was isolated from cycle1 day8 
predose.  
 
Figure 3. High-level FGFR2 amplified cell lines are highly sensitive to FGFR inhibition 
A. FGFR1 copy number and FGFR2 copy number in a panel of 82 breast and 74 gastric 
tumours and cell lines (respectively). FGFR2 amplification has a bimodal distribution with a 
distinct highly amplified population (Bimodality index 2.74). Red indicates tumours with 
response to AZD4547 in the clinic, and light blue tumours that did not respond. 
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B. Western blot of cell lysates from FGFR driven cell lines, blotted for phospho-FGFR 
(Tyr653/654 on FGFR1), FGFR2, and βactin loading control.  
C. Cell line panel was treated with PD173074 for 72 hours, with EC50 (left) and fractional kill 
at 1μM (right). FGFR2 amplified cell lines have higher sensitivity compared to FGFR1 cell 
lines (P=0.0087 and P=0.0109 respectively, Mann-Whitney U Test). MFM223 PIK3CA 
mutant cell line is indicated. 
D. The panel of FGFR driven cell lines was treated with AZD4547 for 72 hours, FGFR2 
amplified cell lines had a lower EC50 than FGFR1 amplified cell lines (p=0.0303, Mann-
Whitney U Test ). 
E. Caspase 3/7 activity in the panel of FGFR driven cell lines was assessed in responses to 
treatment with 50nM AZD4547 for 24 hours and expressed relative to cells treated with 
vehicle. FGFR2 amplified cells have a higher level of apoptosis (p=0.0357, Mann-Whitney U 
Test). 
F. Patient derived xenografts were generated from baseline biopsies of two FGFR2 amplified 
patients that responded to AZD4547 (FG51/pt269 and FG42/pt316). Xenografts were 
established in nude mice and divided randomly into 2 groups treated daily with vehicle and 
AZD4547 12.5mg/kg QD for 2 weeks. For both models, n=4 controls and n=5 AZD4547, 
*p<0.05 and ***p<0.001 2-way ANOVA. 
G. Western blot of cleaved caspase 3 in lysates from FG42/pt316 PDXs treated with vehicle 
or AZD4547 12.5mg/kg QD for 28 hours, with tumours collected 4 hours post last dose of 
AZD4547.  
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Figure 4. Functional genomic screens reveal that PI3 kinase and mTOR signalling 
determines the sensitivity of FGFR2 amplified cell lines to FGFR inhibition 
A. Supervised clustering of the effect of siRNA on sensitivity to PD173074 from parallel 
siRNA screens in FGFR driven cell lines, with the differential effect of siRNA according to 
FGFR2 amplification status. Displayed are the top siRNA with a permutation p value <0.05 
that increase (top) and decrease (bottom) sensitivity to PD173074. Full siRNA screen results 
are in Supplementary Fig. 4A. 
B. Clonogenic survival assays in SUM52 transfected with siCON or siPTEN SMARTpool 
exposed to fixed doses of PD173074 as indicated or vehicle. Data presented as mean with 
SEM (n=3), ***p<0.001 2-way ANOVA. 
C. Western blots of SUM52 cells transfected 72 hours earlier with siCON or siPTEN 
SMARTpool and treated with indicated doses of PD173074 or vehicle for 1 hour, and blotted 
for phospho-AKT S473, total AKT and PTEN 
D. Western blot of a panel of FGFR1 and FGFR2 amplified cell lines treated for indicated 
times with PD173074 500nM, separated by driving FGFR event, blotted for phospho AKT 
S473 and total AKT, phospho ERK1/2 T202/Y204 and total ERK1/2. 
E. Western blot of lysates from patient derived spheroid cultures treated with AZD4547 
100nM or vehicle for 1 hour, probed for phosphorylated forms of FGFR, ERK1,2, AKT, S6, 
and 4EBP1.  
F. Western blot of cell panel treated with AZD4547 50nM for 1h and blotted for phospho-
4EBP1 T37/46, along with total protein and βactin loading control. 
G. 7-methyl-GTP pull down in SUM52 treated with vehicle or AZD4547 for 1 hour, blotted 
with indicated 5’-cap complex members. 
H. FGFR2 amplified cell line SUM52 was cultured in media containing azidohomoalanine 
and treated with and without 50nM AZD4547, relative fluorescence was normalized for cell 
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number. Data is presented as mean with standard deviation (n=5 experiments), P=0.0313 
Wilcoxon matched pairs signed rank test. 
 
Figure 5. Hyperactive FGFR2 in high level amplified cell lines signals to PI3 kinase 
indirectly through ERBB3 and IRS1/IGF1R 
A. SUM52 lysates were immunoprecipitated with antibodies against p85 PI3K, FGFR2, or 
control IgG, and blotted as indicated. 
B. Phospho-receptor tyrosine kinase array of SUM52 cells (left) and SNU16 cells (right) 
treated with PD173074 or control for 1 hour. 
C. Phospho-receptor tyrosine kinase array (left panel) of patient derived xenograft FG42 
(pt316) with vehicle or AZD4547 12.5mg/kg QD for 28 hours, with tumours collected 4 hours 
post last dose of AZD4547. Western blots (right panel) of lysates from FG42 (pt316) treated 
with AZD4547 as described, probed for phospho-HER2, phospho-ERBB3, phospho-FGFR, 
and total proteins as indicated. 
D. SNU16 cells were treated with vehicle or 500nM PD173074, lysates immunoprecipitated 
with ERBB3 or control antibody, and blotted for FGFR2, ERBB3, and p85 PI3K. 
E. Western blots of Snu16 (left) and SUM52 (right) cells grown in complete media were 
transfected 72 hours earlier with multiple siRNA targeting ERBB3 or siCON, blotted with 
indicated antibodies 
F. SNU16 were treated with vehicle or PD170374 500nM for 1h and blotted for phospho-
AKT T308 and S473, phospho-ERK 1/2 T202/Y204, phospho-IGF1R Y1135 and phospho-
FGFR Y653/654) and total proteins as indicated. 
High-level clonal FGFR2 amplification and treatment response 
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G. SNU16 cells were treated with IGF1R inhibitor 250nM AEW541 for 1 hour and blotted for 
phospho-AKT S473, phospho-ERK1/2 T202/Y204, phospho-IGF1R Y1135, phospho-FGFR 
and total proteins as indicated. 
H. SNU16 were treated with vehicle, PD170374 500nM or AEW541 250nM for 1hour, 
lysates were precipitated with RAF1 Ras binding domain, and blotted with pan-RAS antibody 
to assess the level of GTP bound RAS. 
I. Lysates of SNU16 cells treated with 500nM PD173074, 250nM AEW541, or the 
combination were immunoprecipitated with a p85 PI3K antibody or control IgG and blotted 
for IRS1, ERBB3 and p85. 
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